Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

The Effect of Oxytocin on Gastric Emptying

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bodil Ohlsson, Skane University Hospital
ClinicalTrials.gov Identifier:
NCT01152047
First received: June 23, 2010
Last updated: April 6, 2015
Last verified: April 2015
History of Changes

June 23, 2010
April 6, 2015
May 2010
April 2015   (final data collection date for primary outcome measure)
Satiety [ Time Frame: 2 h ] [ Designated as safety issue: No ]
The investigator want to examine whether oxytocin leads to lower satiety scores after intake of the same volume of nutrient
  • Satiety [ Time Frame: 2 h ] [ Designated as safety issue: No ]
    The investigator want to examine whether oxytocin leads to lower satiety scores after intake of the same volume of nutrient
  • To see if oxytocin lowers satiety [ Time Frame: 2h ] [ Designated as safety issue: No ]
    To perform a drinking satiety test twice. Once with oxytocin and once with saline. Then examine whether oxytocin decreases satiety compared to saline
Complete list of historical versions of study NCT01152047 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
To see if oxytocin lowers satiety [ Time Frame: 2h ] [ Designated as safety issue: No ]
To perform a drinking satiety test twice. Once with oxytocin and once with saline. Then examine whether oxytocin decreases satiety compared to saline
Not Provided
 
The Effect of Oxytocin on Gastric Emptying
The Effect of Oxytocin on Satiety in Patients With Dyspepsia
The investigators have seen that oxytocin lowers satiety in healthy subjects. Patients with dyspepsia suffers from decreased accommodation and increased satiety postprandially. The investigators now want to examine whether oxytocin may diminish symptoms in these patients.
Patients will come twice for a slow satiety drinking test. Once they will get saline infusion and once oxytocin 40 mU/min. At the same time they register satiety on a VAS scale.
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
  • Dyspepsia
  • Lack of Satiety
Drug: oxytocin
40mU/min as infusion of oxytocin
Other Name: syntocinon
Experimental: oxytocin, satiety
Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
Intervention: Drug: oxytocin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
14
April 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Dyspepsia

Exclusion Criteria:

  • Age > 65 years
  • Cardiac disease
Both
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT01152047
2009/502, 2009/502
No
Not Provided
Not Provided
Bodil Ohlsson, Skane University Hospital
Skane University Hospital
Not Provided
Principal Investigator: Bodil Ohlsson, professor Divsion of Internal Medicine
Skane University Hospital
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP